Search Results

You are looking at 101 - 110 of 470 items for :

  • "paclitaxel" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

William J. Gradishar

=.0067) but clinically modest 1.3-month progression-free survival benefit. 9 In the first-line setting of the BOLERO-1/TRIO 019 trial, trastuzumab/paclitaxel/everolimus did not improve progression-free survival overall. However, in the hormone receptor

Full access

Bryan J. Schneider

. Phase III study of oral compared to intravenous topotecan as second-line therapy in small-cell lung cancer . J Clin Oncol 2007 ; 25 : 2086 – 2092 . 14. Dy GK Jett JR Geoffroy FJ . Topotecan and paclitaxel in previously treated patients

Full access

Robert J. Morgan, Ronald D. Alvarez, Deborah K. Armstrong, Robert A. Burger, Mariana Castells, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David Gershenson, Heidi Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O’Malley, Richard T. Penson, Steven W. Remmenga, Paul Sabbatini, Joseph T. Santoso, Russell J. Schilder, Julian Schink, Nelson Teng, Theresa L. Werner, Miranda Hughes, and Mary A. Dwyer

to up-front therapy with carboplatin/paclitaxel or using bevacizumab as maintenance therapy; this disagreement is reflected as a category 3 recommendation. Most panel members believe that bevacizumab should not be added to up-front chemotherapy in

Full access

Margaret Tempero

FOLFIRINOX [5-FU, leucovorin, irinotecan, and oxaliplatin] or gemcitabine) and the APACT study (NCT01964430; surgery followed by either gemcitabine/nanoparticle albumin-bound [nab]-paclitaxel or gemcitabine monotherapy). Turning to neoadjuvant therapy, Dr

Full access

Melinda Telli

ductal carcinoma who has triple-negative disease and no BRCA1 or BRCA2 mutation identified would be an anthracycline and taxane-based regimen, such as the regimen of dose-dense doxorubicin and cyclophosphamide followed by dose-dense paclitaxel

Full access

Melinda L. Telli and Ronald M. Witteles

-stage disease settings. After its initial FDA approval in 1998 for first-line treatment of HER2-positive metastatic breast cancer in combination with paclitaxel, a series of pivotal adjuvant studies documented statistically significant improvements in both

Full access

Lainie Martin and Russell J. Schilder

trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model . Clin Cancer Res 2005 ; 11 ( 19 Pt 1 ): 6966 – 6971 . 30. Eleutherakis-Papaiakovou V Bamias A Dimopoulos MA

Full access

Jaffer A. Ajani

. Kelsey CR Chino JP Willett CG . Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer . Int J Radiat Oncol Biol Phys 2007 ; 69 : 770 – 776 . 12. Javeri H Arora R Correa AM . Influence of induction

Full access

Dena Jaffe, Marc DeCongelio, and Joseph Gricar

(Asia=71.1%; West=89.0%). The five most common 1L treatment regimens were cisplatin + 5-FU (27.4%), carboplatin + paclitaxel (8.4%), FOLFOX (8.0%), 5-FU (+leucovorin) (6.6%), and carboplatin + 5-FU (5.9%), although differences were observed by geography

Full access

Luke Proctor, Arjith Rathakrishnan, Claudia Zapata, and KanwarAnoop Kainaur

chemotherapy as per Keynote-407 (pembrolizumab, carboplatin and paclitaxel) due to continuous effusions, followed by protocol Keynote-189 (pembrolizumab, cisplatin, pemetrexed). Once his molecular testing revealed an EML4-ALK fusion, he was switched to oral